RU2011140491A - Конъюгаты антитело-лекарственное средство, которые связывают белки 24р4с12 - Google Patents
Конъюгаты антитело-лекарственное средство, которые связывают белки 24р4с12 Download PDFInfo
- Publication number
- RU2011140491A RU2011140491A RU2011140491/10A RU2011140491A RU2011140491A RU 2011140491 A RU2011140491 A RU 2011140491A RU 2011140491/10 A RU2011140491/10 A RU 2011140491/10A RU 2011140491 A RU2011140491 A RU 2011140491A RU 2011140491 A RU2011140491 A RU 2011140491A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- drug conjugate
- mammal
- fragment
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15814309P | 2009-03-06 | 2009-03-06 | |
| US61/158,143 | 2009-03-06 | ||
| PCT/US2010/026429 WO2010111018A1 (en) | 2009-03-06 | 2010-03-05 | Antibody drug conjugates (adc) that bind to 24p4c12 proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011140491A true RU2011140491A (ru) | 2013-04-20 |
Family
ID=42781369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011140491/10A RU2011140491A (ru) | 2009-03-06 | 2010-03-05 | Конъюгаты антитело-лекарственное средство, которые связывают белки 24р4с12 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8309093B2 (enExample) |
| EP (1) | EP2403524A4 (enExample) |
| JP (1) | JP2012519711A (enExample) |
| KR (1) | KR20120034591A (enExample) |
| CN (1) | CN102448486A (enExample) |
| AU (1) | AU2010229192A1 (enExample) |
| BR (1) | BRPI1013645A2 (enExample) |
| CA (1) | CA2754531A1 (enExample) |
| IL (1) | IL214983A0 (enExample) |
| MX (1) | MX2011009281A (enExample) |
| RU (1) | RU2011140491A (enExample) |
| SG (1) | SG174259A1 (enExample) |
| TW (1) | TW201043249A (enExample) |
| WO (1) | WO2010111018A1 (enExample) |
| ZA (1) | ZA201107293B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010229192A1 (en) * | 2009-03-06 | 2011-09-29 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 24P4C12 proteins |
| CA2830349C (en) | 2011-03-17 | 2019-07-16 | The University Of Birmingham | Re-directed immunotherapy |
| US9796754B2 (en) * | 2011-05-27 | 2017-10-24 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| PT2887959T (pt) * | 2012-08-23 | 2019-02-01 | Seattle Genetics Inc | Conjugados anticorpo-fármaco (adc) que se ligam a proteínas 158p1d7 |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| US9089614B2 (en) | 2012-12-21 | 2015-07-28 | Bioalliance C.V. | Hydrophilic self-immolative linkers and conjugates thereof |
| EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
| US20170043034A1 (en) * | 2014-01-24 | 2017-02-16 | Genentech, Inc. | Methods of using anti-steap1 antibodies and immunoconjugates |
| CN110845616A (zh) | 2014-03-21 | 2020-02-28 | 艾伯维公司 | 抗-egfr抗体及抗体药物偶联物 |
| PL3134125T3 (pl) | 2014-04-25 | 2020-04-30 | Pierre Fabre Médicament | Koniugat przeciwciało-lek i jego zastosowanie do leczenia raka |
| UA120364C2 (uk) | 2014-04-25 | 2019-11-25 | Пьєр Фабр Медікамент | Кон'югат антитіла до igf-1r з лікарським засобом |
| JP2017528418A (ja) | 2014-06-20 | 2017-09-28 | バイオアライアンス コマンディテール フェンノートシャップ | 抗葉酸受容体アルファ（ｆｒａ）抗体−薬物コンジュゲート及びその使用方法 |
| CN106659783A (zh) * | 2014-06-20 | 2017-05-10 | 艾比吉诺米克斯国际股份有限公司 | Her2抗体‑药物缀合物 |
| AU2015282627B2 (en) | 2014-06-30 | 2020-04-02 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| CA2971634C (en) | 2014-12-23 | 2024-06-04 | Nbe-Therapeutics Ag | Binding protein drug conjugates comprising anthracycline derivatives |
| ES2880731T3 (es) | 2016-01-08 | 2021-11-25 | Altrubio Inc | Anticuerpos anti-PSGL-1 tetravalentes y usos de los mismos |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| WO2017214456A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| MX2018015272A (es) | 2016-06-08 | 2019-08-12 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
| CN109563167A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
| PL3458479T4 (pl) | 2016-06-08 | 2021-07-26 | Abbvie Inc. | Przeciwciała anty-b7-h3 i koniugaty przeciwciało-lek |
| WO2017214339A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| CN113004417A (zh) | 2017-09-07 | 2021-06-22 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| AU2019402097A1 (en) | 2018-12-17 | 2021-06-10 | Revitope Limited | Twin immune cell engager |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4742000A (en) | 1986-05-02 | 1988-05-03 | University Of Chicago | Antibody to human progesterone receptor and diagnostic materials and methods |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| US20030082546A1 (en) | 1996-11-06 | 2003-05-01 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6800746B2 (en) | 1997-02-25 | 2004-10-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US7109318B2 (en) | 1997-06-16 | 2006-09-19 | Genentech, Inc. | Nucleic acids encoding PRO830 |
| US20030083461A1 (en) | 1997-06-16 | 2003-05-01 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7393663B2 (en) | 1997-08-01 | 2008-07-01 | Serono Genetics Institute S.A. | Expressed sequence tags and encoded human proteins |
| US7160985B2 (en) | 1997-10-29 | 2007-01-09 | Genentech, Inc. | Pro180 polypeptide |
| AU764441B2 (en) | 1998-02-09 | 2003-08-21 | Genset S.A. | cDNAs encoding secreted proteins |
| US6747137B1 (en) | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
| US6551795B1 (en) | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| US20030050465A1 (en) | 1998-08-10 | 2003-03-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| CA2296792A1 (en) | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| US7109292B2 (en) | 1999-03-08 | 2006-09-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7244827B2 (en) | 2000-04-12 | 2007-07-17 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
| US6943235B1 (en) | 1999-04-12 | 2005-09-13 | Agensys, Inc. | Transmembrane protein expressed in prostate cancer |
| WO2000061746A1 (en) | 1999-04-12 | 2000-10-19 | Agensys, Inc. | 13 transmembrane protein expressed in prostate cancer |
| EP1074617A3 (en) | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
| FR2800750B1 (fr) | 1999-11-05 | 2003-01-31 | Centre Nat Rech Scient | Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline |
| US20020192763A1 (en) | 2000-04-17 | 2002-12-19 | Jiangchun Xu | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US20030099974A1 (en) | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
| US20030073623A1 (en) | 2001-07-30 | 2003-04-17 | Drmanac Radoje T. | Novel nucleic acid sequences obtained from various cDNA libraries |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7202335B2 (en) | 2001-12-06 | 2007-04-10 | Genentech, Inc. | PRO300 polypeptides |
| AU2003222225A1 (en) | 2002-02-20 | 2003-09-09 | Incyte Corporation | Receptors and membrane-associated proteins |
| CA2802205C (en) * | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| JP2006508163A (ja) * | 2002-11-27 | 2006-03-09 | アジェンシス， インコーポレイテッド | 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質 |
| NZ583292A (en) * | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| WO2006017538A2 (en) * | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| US20070160617A1 (en) | 2005-06-20 | 2007-07-12 | Psma Development Company, Llc | PSMA antibody-drug conjugates |
| US20080311107A1 (en) | 2006-02-17 | 2008-12-18 | Genetech, Inc. | Novel Gene Disruptions, Compositions and Methods Relating Thereto |
| PL2185574T3 (pl) * | 2007-09-07 | 2013-09-30 | Agensys Inc | Przeciwciała i powiązane cząsteczki, które wiążą się do białek 24P4C12 |
| US8039597B2 (en) * | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
| AU2010229192A1 (en) * | 2009-03-06 | 2011-09-29 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 24P4C12 proteins |
-
2010
- 2010-03-05 AU AU2010229192A patent/AU2010229192A1/en not_active Abandoned
- 2010-03-05 CN CN2010800203364A patent/CN102448486A/zh active Pending
- 2010-03-05 JP JP2011553153A patent/JP2012519711A/ja active Pending
- 2010-03-05 EP EP10756560A patent/EP2403524A4/en not_active Withdrawn
- 2010-03-05 CA CA2754531A patent/CA2754531A1/en not_active Abandoned
- 2010-03-05 RU RU2011140491/10A patent/RU2011140491A/ru not_active Application Discontinuation
- 2010-03-05 US US12/718,902 patent/US8309093B2/en active Active
- 2010-03-05 BR BRPI1013645A patent/BRPI1013645A2/pt not_active IP Right Cessation
- 2010-03-05 WO PCT/US2010/026429 patent/WO2010111018A1/en not_active Ceased
- 2010-03-05 SG SG2011063930A patent/SG174259A1/en unknown
- 2010-03-05 KR KR1020117023550A patent/KR20120034591A/ko not_active Withdrawn
- 2010-03-05 MX MX2011009281A patent/MX2011009281A/es unknown
- 2010-03-08 TW TW099106660A patent/TW201043249A/zh unknown
-
2011
- 2011-09-05 IL IL214983A patent/IL214983A0/en unknown
- 2011-10-05 ZA ZA2011/07293A patent/ZA201107293B/en unknown
-
2012
- 2012-11-08 US US13/672,419 patent/US20130136756A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2403524A1 (en) | 2012-01-11 |
| WO2010111018A1 (en) | 2010-09-30 |
| US20130136756A1 (en) | 2013-05-30 |
| CN102448486A (zh) | 2012-05-09 |
| KR20120034591A (ko) | 2012-04-12 |
| MX2011009281A (es) | 2012-07-30 |
| BRPI1013645A2 (pt) | 2019-07-02 |
| AU2010229192A1 (en) | 2011-09-29 |
| SG174259A1 (en) | 2011-10-28 |
| US20100330107A1 (en) | 2010-12-30 |
| ZA201107293B (en) | 2012-06-27 |
| WO2010111018A8 (en) | 2011-03-03 |
| JP2012519711A (ja) | 2012-08-30 |
| CA2754531A1 (en) | 2010-09-30 |
| US8309093B2 (en) | 2012-11-13 |
| TW201043249A (en) | 2010-12-16 |
| EP2403524A4 (en) | 2012-09-26 |
| IL214983A0 (en) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011140491A (ru) | Конъюгаты антитело-лекарственное средство, которые связывают белки 24р4с12 | |
| JP2012519711A5 (enExample) | ||
| RU2483080C2 (ru) | Антитела и иммуноконъюгаты и их применение | |
| RU2423382C1 (ru) | Композиции и способы диагностики и лечения опухоли | |
| ES2879799T3 (es) | Anticuerpo anti-HER2 y conjugado del mismo | |
| RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| JP2016063817A5 (enExample) | ||
| JP2017110002A5 (enExample) | ||
| RU2014138040A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| CY1112473T1 (el) | Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα | |
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| RU2013142004A (ru) | Конъюгаты "антитело-лекарственное средство" | |
| RU2008141171A (ru) | Анти-тат226 антитела и иммуноконъюгаты | |
| JP2010523469A5 (enExample) | ||
| JP2013543498A5 (enExample) | ||
| RU2009148600A (ru) | Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток | |
| RU2018134331A (ru) | Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения | |
| JP2013518912A5 (enExample) | ||
| RU2014120629A (ru) | Антиген-связывающий белок и его применение в качестве продукта для адресной доставки при лечении рака | |
| JP2008546780A5 (enExample) | ||
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| JP2010526821A5 (enExample) | ||
| JP2011504460A5 (enExample) | ||
| RU2012137498A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| JP2010537671A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140811 |